[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination]

Rinsho Ketsueki. 2021;62(11):1639-1642. doi: 10.11406/rinketsu.62.1639.
[Article in Japanese]

Abstract

Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic until today, but treatment options remain limited. COVID-19 vaccination is expected to decrease the number of patients with COVID-19 worldwide. In Japan, two types of mRNA COVID-19 vaccine, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have been approved and administered. However, their side effects remain poorly elucidated. This paper presents two cases of immune thrombocytopenia (ITP) after BNT162b2 mRNA COVID-19 vaccination. Whether or not ITP is triggered by the vaccination or not is difficult to identify. Further investigation with a large number of cases is warranted to clarify the side effects of BNT162b2 mRNA COVID-19 vaccination.

Keywords: COVID-19; Immune thrombocytopenia; SARS-CoV-2 vaccine.

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Purpura, Thrombocytopenic, Idiopathic*
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine